Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial

OBJECTIVE The Diabetes Control and Complications Trial (DCCT) demonstrated the beneficial effects of intensive versus conventional therapy on the development and progression of microvascular complications of type 1 diabetes. These beneficial effects were almost completely explained by the difference between groups in the levels of HbA1c, which in turn were associated with the risk of these complications. We assessed the association of glucose variability within and between quarterly 7-point glucose profiles with the development and progression of retinopathy, nephropathy, and cardiovascular autonomic neuropathy during the DCCT. RESEARCH DESIGN AND METHODS Measures of variability included the within-day and updated mean (over time) of the SD, mean amplitude of glycemic excursions (MAGE), and M-value, and the longitudinal within-day, between-day, and total variances. Imputation methods filled in the 16.3% of expected glucose values that were missing. RESULTS Cox proportional hazards models assessed the association of each measure of glycemic variation, as a time-dependent covariate, with the risk of retinopathy and nephropathy, and a longitudinal logistic regression model did likewise for cardiovascular autonomic neuropathy. Adjusted for mean blood glucose, no measure of within-day variability was associated with any outcome. Only the longitudinal mean M-value (over time) was significantly associated with microalbuminuria when adjusted for the longitudinal mean blood glucose and corrected for multiple tests using the Holm procedure. CONCLUSIONS Overall, within-day glycemic variability, as determined from quarterly glucose profiles, does not play an apparent role in the development of microvascular complications beyond the influence of the mean glucose.

[1]  T. Hansen,et al.  Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777–783 , 2017, Diabetes Care.

[2]  Lena Osterhagen,et al.  Multiple Imputation For Nonresponse In Surveys , 2016 .

[3]  Ajit S. Divakaruni,et al.  GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop , 2015, Diabetes.

[4]  D. Nathan,et al.  Relationship of Glycated Albumin to Blood Glucose and HbA1c Values and to Retinopathy, Nephropathy, and Cardiovascular Outcomes in the DCCT/EDIC Study , 2013, Diabetes.

[5]  Stef van Buuren,et al.  Flexible Imputation of Missing Data , 2012 .

[6]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[7]  D. Rodbard,et al.  The Minimum Frequency of Glucose Measurements from Which Glycemic Variation Can Be Consistently Assessed , 2010, Journal of diabetes science and technology.

[8]  A. Rigby,et al.  Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT , 2009, Diabetologia.

[9]  A. Rigby,et al.  Effect of Glucose Variability on the Long-Term Risk of Microvascular Complications in Type 1 Diabetes , 2009, Diabetes Care.

[10]  S. Rodriguez-Segade,et al.  Translating the A1C Assay Into Estimated Average Glucose Values , 2009, Diabetes Care.

[11]  D. Schoenfeld,et al.  Translating the A1C Assay Into Estimated Average Glucose Values , 2008, Diabetes Care.

[12]  A. Rigby,et al.  A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes , 2008, Diabetes Care.

[13]  B. Zinman,et al.  Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited , 2008, Diabetes.

[14]  E. Kilpatrick,et al.  Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes , 2008, Diabetologia.

[15]  E. Kilpatrick,et al.  Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes , 2007, Diabetologia.

[16]  Michael Brownlee,et al.  The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes , 2007, Diabetes Care.

[17]  G. Bolli.  Glucose Variability and Complications , 2006, Diabetes Care.

[18]  Jean-Paul Cristol,et al.  Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. , 2006, JAMA.

[19]  Michael Brownlee,et al.  Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. , 2006, Journal of the American Medical Association (JAMA).

[20]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[21]  J. Schafer,et al.  Computational Strategies for Multivariate Linear Mixed-Effects Models With Missing Values , 2002 .

[22]  P. O'Brien,et al.  The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial , 2001, Diabetologia.

[23]  John M. Lachin,et al.  Biostatistical Methods: The Assessment of Relative Risks , 2000 .

[24]  V. Kadirkamanathan.  The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT) , 1998, Diabetologia.

[25]  The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. , 1996, Diabetes.

[26]  The Relationship of Glycemic Exposure (HbA1c) to the Risk of Development and Progression of Retinopathy in the Diabetes Control and Complications Trial , 1995, Diabetes.

[27]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[28]  Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.

[29]  R. Rizza,et al.  Measurements of Glucose Control , 1987, Diabetes Care.

[30]  D. Rubin,et al.  Multiple Imputation for Interval Estimation from Simple Random Samples with Ignorable Nonresponse , 1986 .

[31]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[32]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[33]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .

[34]  W. F. Taylor,et al.  Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability , 1970, Diabetes.

[35]  J. Schlichtkrull,et al.  [M-VALUE, AN INDEX FOR BLOOD SUGAR CONTROL IN DIABETICS]. , 1964, Ugeskrift for laeger.